Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 5/2017

01-05-2017 | Original Article

Prospective cohort study of cancer patients diagnosed with incidental venous thromboembolism on routine computed tomography scans

Authors: Carmen P. Escalante, Gregory W. Gladish, Wei Qiao, Ali Zalpour, Binara Assylbekova, Shuwei Gao, Kelechi A. Olejeme, Marsha N. Richardson, Maria E. Suarez-Almazor

Published in: Supportive Care in Cancer | Issue 5/2017

Login to get access

Abstract

Purpose

Venous thromboembolism (VTE) is a major complication of cancer with recent increasing reports of incidental VTE. The objectives are to estimate the prevalence of incidental VTE in cancer patients on staging CT scans, identify common symptoms, and determine VTE recurrence in a prospective study.

Patients and methods

One thousand ninety patients were studied. Adult cancer patients scheduled for outpatient staging CT scans were eligible. VTE cases were followed for 6 months. Fisher’s exact test for group comparisons of categorical variables and generalized linear modeling to estimate the prevalence of incidental VTE was used.

Results

The mean age was 58 years (range 18–87 years); 50% were male. The prevalence of incidental VTE was 1.8% (CI 1.15–2.87%). Significant symptoms in patients with VTE included fatigue (p = 0.004), stress (p = 0.0195), depression (p = 0.019), poorer quality of life (p = 0.0194), and poorer physical well-being (p = 0.0007). All the patients with VTE had at least one comorbidity (p = 0.03). No patient had recurrence within 6 months.

Conclusion

The prevalence of incidental VTE on staging CT scans is lower than previously reported. Symptoms were associated with VTE; however, further work is needed to understand whether these are clinically relevant. No VTE recurrences were noted following 6 months.
Literature
1.
Khorana AA, Francis CW, Culakova E et al (2006) Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24:494–490CrossRef
2.
Sallah S, W.J., Nguyen NP, Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost, 2002. 87: p. 575–579.
3.
Stein PD, Beemath A, Meyers FA et al. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 4:60–68
4.
Chew HK et al (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458–464CrossRefPubMed
5.
Stein PD, Beemath A, Matta F et al (2007) Clinical characteristics of patients with acute pulmonary embolism: data from PIOPED I. Am J Med 120(10):871–879CrossRefPubMedPubMedCentral
6.
Reidel M (2001) Acute pulmonary embolism 1: pathophysiology, clinical presentation and diagnosis. Heart 85:229–240CrossRef
7.
Kucher N (2011) Clinical practice. Deep-vein thrombosis of the upper extremities. N Engl J Med 364:861–869CrossRefPubMed
8.
O'Connell CL et al (2006) Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol 24(30):4928–4932CrossRefPubMed
9.
Mendoza TR et al (1999) The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85(5):1186–1196CrossRefPubMed
10.
Cleeland CS et al (2000) Assessing symptom distress in cancer patients: the M.D. Anderson symptom inventory. Cancer 89(7):1634–1646CrossRefPubMed
11.
Tanaka K et al (2002) Prevalence and screening of dyspnea interfering with daily life activities in ambulatory patients with advanced lung cancer. J Pain Symptom Manag 23(6):484–489CrossRef
12.
Tanaka K et al (2000) Development and validation of the Cancer Dyspnoea Scale: a multidimensional, brief, self-rating scale. Br J Cancer 82(4):800–805CrossRefPubMedPubMedCentral
13.
Oken MM et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–655CrossRefPubMed
14.
Lovinbond SH, Lovibond PF (1995) Manual for depression, anxiety and stress scales, 2nd edn. Psyhology Foundation of Australia, Sydney
15.
Cella D, Hahn EA, Dineen K (2002) Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res 11(3):207–221CrossRefPubMed
16.
Webster K, Cella D, Yost K (2003) The F unctional A ssessment of C hronic I llness T herapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 1:79CrossRefPubMedPubMedCentral
17.
Loud PA, Katz DS, Bruce DA et al (2001) Deep venous thrombosis with suspected pulmonary embolism: detection with combined CT venography and pulmonary angiography. Radiology 219:498–502CrossRefPubMed
18.
Fujikawa A, Matsuoka S, Kuramochi K et al (2011) Vascular enhancement and image quality of CT venography: comparison of standard and low kilovoltage settings. AJR Am J Roentgenol 197:838–843CrossRefPubMed
19.
Kaatz S et al (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13(11):2119–2126CrossRefPubMed
20.
Gladish GW et al (2006) Incidental pulmonary emboli in oncology patients: prevalence, CT evaluation, and natural history. Radiology 240(1):246–255CrossRefPubMed
21.
Cronin CG et al (2007) Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. AJR Am J Roentgenol 189(1):162–170CrossRefPubMed
22.
Winston CB et al (1996) Incidental pulmonary emboli detected at helical CT: effect on patient care. Radiology 201(1):23–27CrossRefPubMed
23.
Gosselin MV et al (1998) Unsuspected pulmonary embolism: prospective detection on routine helical CT scans. Radiology 208(1):209–215CrossRefPubMed
24.
Storto ML et al (2005) Incidental detection of pulmonary emboli on routine MDCT of the chest. AJR Am J Roentgenol 184(1):264–267CrossRefPubMed
25.
Heit JA et al (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 162(11):1245–1248CrossRefPubMed
Metadata
Title
Prospective cohort study of cancer patients diagnosed with incidental venous thromboembolism on routine computed tomography scans
Authors
Carmen P. Escalante
Gregory W. Gladish
Wei Qiao
Ali Zalpour
Binara Assylbekova
Shuwei Gao
Kelechi A. Olejeme
Marsha N. Richardson
Maria E. Suarez-Almazor
Publication date
01-05-2017
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 5/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3559-6

Other articles of this Issue 5/2017

Supportive Care in Cancer 5/2017 Go to the issue

Original Article

Quality of life of older African American breast cancer survivors: a population-based study

Commentary

An exploratory study of the worst-case scenario exercise as an exposure treatment for fear of cancer recurrence

Review Article

The life experience of nutrition impact symptoms during treatment for head and neck cancer patients: a systematic review and meta-synthesis

Original Article

Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT)

Original Article

Fear of recurrence or progression as a link between somatic symptoms and perceived stress among cancer survivors

Original Article

Experiences with the survivorship care plan in primary care providers of childhood cancer survivors: a mixed methods approach
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits